Epidemiology, Risk Factors, and Diagnosis Basics

Apuntes

systemic agents B Antiangiogenic and targeted therapy in thyroid carcinoma A. Papillary, follicular, and oncocytic carcinoma derive from epithelial follicular cells and are classified as differentiated thyroid cancers. High-grade differentiated thyroid carcinoma, poorly differentiated thyroid carcinoma, and poorly differentiated thyroid carcinoma, oncocytic subtype are advanced forms of thyroid cancer. Anaplastic thyroid carcinoma is an undifferentiated and the most lethal form of thyroid cancer. Medullary thyroid carcinoma derives from parafollicular C cells. B. Drugs in green are antiangiogenic multikinase inhibitors. Drugs in blue are targeted inhibitors. Proteins derived from gene fusions are in pink and purple. c-MET indicates mesenchymal epithelial transition factor; FGFR, fibroblast growth factor receptor; PDGFR, platelet derived growth factor receptor; RET, rearranged during transfection, and VEGFR, vascular endothelial growth factor receptor. Clinical Review & Education Review Thyroid Cancer—A Review 426 JAMA February 6, 2024 Volume 331, Number 5 (Reprinted) jama.com © 2024 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by Cleveland Clin...